SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events
This video was recorded during the digital ESC Congress 2021.
Prof. Stefan D. Anker is Head of Field “Tissue Homeostasis and Cachexia" at Charité University, Berlin, Germany.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: